Oncolytics Biotech Inc. Files October 2024 6-K Update
Ticker: ONCY · Form: 6-K · Filed: Oct 4, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, foreign-private-issuer
Related Tickers: ONCY
TL;DR
ONCY filed a 6-K for Oct 2024 - standard update.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on October 4, 2024, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is primarily involved in the Pharmaceutical Preparations industry. This filing is an update for the month of October 2024.
Why It Matters
This filing serves as a routine corporate update for investors and regulatory bodies, indicating ongoing operational status for Oncolytics Biotech Inc.
Risk Assessment
Risk Level: low — This is a routine corporate filing (6-K) and does not contain specific financial or operational news that would inherently increase risk.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer
- 0001129928-24-000064 (filing_id) — Accession Number
- 20241004 (date) — Filing Date
- Calgary, Alberta, Canada (location) — Company Headquarters
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the filer of this document?
The filer is ONCOLYTICS BIOTECH INC.
When was this report filed?
The report was filed on October 4, 2024.
What is the primary business of Oncolytics Biotech Inc.?
Oncolytics Biotech Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Oncolytics Biotech Inc. located?
The company's principal executive offices are located in Calgary, Alberta, Canada.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-10-04 08:00:11
Filing Documents
- form6koncycorporateupdate.htm (6-K) — 18KB
- oncycorporateupdatepr.htm (EX-99.1) — 28KB
- 0001129928-24-000064.txt ( ) — 46KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date October 4, 2024 Kirk Look Chief Financial Officer